[Course modifying therapy of Alzheimer's dementia].
The current therapy of Alzheimer's disease is primarily symptomatic. Drugs which aim to modify the course of the disease are currently being developed and tested in clinical trials. Given the complex and partly unknown pathogenesis of the disease, failure of such forms of therapy has to be taken into account. Clinical epidemiology suggests a possible neuroprotective effect of statins and non-steroidal anti-inflammatory drugs, however, the molecular basis of these effects has to be further unraveled. Therapies that modify the course of Alzheimer's disease are only likely to be effective years if not decades before the disease becomes clinically apparent. Thus, the therapy of risk factors including arterial hypertension and obesity in midlife as well as a Mediterranean diet currently provides the highest chance of modifying the course of the disease.
Heneka
M T
MT
Klinische Neurowissenschaften, Klinik und Poliklinik für Neurologie, Universität Bonn, Bonn, Deutschland. michael.heneka@ukb.uni-bonn.de
D000544:Alzheimer Disease / Q000150:complications* / Q000628:therapy*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D003704:Dementia / Q000150:complications* / Q000628:therapy*; D038441:Diet, Mediterranean; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018696:Neuroprotective Agents